Disk susceptibility tests with two structurally related aminoglycosides (amikacin and Sch 21420) were evaluated. Tests with 10-and 30-,ug amikacin disks confirmed previous recommendations for interpretive zone standards; 30-,ug disks are preferred. Tests with 10-, 20-, and 30-,ug Sch 21420 disks led to similar conclusions. The 30-,ug Sch 21420 disks are recommended, with zone standards of c14 mm for the resistant category (minimal inhibitory concentration, 232 ,Lg/ml) and 217 mm for the susceptible category (miniimal inhibitory concentration, -16
,tg/ml). If a minimal inhibitory concentration breakpoint of c8 ,ug/ml is preferred for defining the susceptible category, somewhat different zone standards may be used (c15 mm and 219 mm). Further evaluation documented the fact that tests with 30-,ug amikacin disks predicted resistance or susceptibility to Sch 21420 almost as well as did a 30-,ug Sch 21420 disk. Thus, the class concept of disk testing was judged to be applicable, and routine testing with Sch 21420 may not be required.
Sch 21420 is a semisynthetic aminoglycoside which is produced from gentamicin B by a process similar to that used to produce amikacin from kanamycin A (9) . The in vitro activity of Sch 21420 is similar to that of amikacin (2, 11- 13, 16 ), but Sch 21420 has the potential for diminished nephrotoxicity (6). The present report summarizes our efforts to establish interpretive zone standards for Sch 21420 disk susceptibility tests using 10-, 20-, and 30-,ug disks.
Furthermore, efforts were made to determine whether tests with amikacin disks could be used to predict susceptibility to Sch 21420.
Amikacin susceptibility tests were initially standardized by using 10-,ug disks and zone size breakpoints of -11 mm for the resistant category and -14 mm for the susceptible category. Moellering et al. (8) found that these disk test standards were unacceptable; i.e., nearly half of the microorganisms which were found to be resistant by the disk technique were actually found to be susceptible by a dilution procedure. Washington et al. (15) reported a collaborative study designed to reevaluate disk susceptibility test standards for 10-and 30-,ug amikacin disks. They recommended zone size breakpoints of c9 mm and 212 mm for 10-pug disks, but they preferred tests with 30-,ug disks and zone standards of c14 mm and 217 mm. In 1979, the National Committee for Clinical Laboratory Standards (NCCLS) subcommittee on antimicrobial susceptibility tests reviewed the above references and data from other unpublished studies. This led to a recommendation that 30-,ug amikacin disks should be used, with appropriate zone size breakpoints (10) . The present report includes confirmatory data which support the current NCCLS recommendations for amikacin disk tests.
Like previous authors (8, 15), we initially utilized minimal inhibitory concentration (MIC) breakpoints of -32 ,ug/ml for the resistant category and -16,ug/ml for the susceptible category.
Farchione and Chudzik (2) have suggested that therapy with amikacin may be successful even when the peak blood level only slightly exceeds the MIC for the pathogen being treated. Peak blood levels of both amikacin and Sch 21420 rarely exceed 25 to 30 ag/ml. Consequently, strains with amikacin MICs of 16 ,ug/ml should not be considered resistant, and those with MICs of _8,ug/ml are clearly susceptible. Sufficient clinical experience with Sch 21420 has not yet been gathered to determine whether strains which are inhibited by 16 ,Lg/ml will be responsive to therapy. With both drugs, a conservative categorization would include all strains with MICs of c8 ug/ml in the susceptible category and those inhibited by 16 ,tg/ml in an intermediate category, i.e., neither resistant nor une-on October 25, 2017 by guest http://aac.asm.org/ Downloaded from VOL. 18, 1980 quivocally susceptible. This alternative approach to categorization was considered in analyzing the data in the present report.
MATERIALS AND METHODS
Tests were performed at the Center for Disease Control, Atlanta, Ga., and at the University of California (Davis) Medical Center, Sacramento. Data collected in these two centers were combined after comparable results were demonstrated by previously described (1, 4) control procedures.
Both laboratories performed the disk diffusion technique as outlined by the NCCLS (10) . Tests included the use of disks containing 10, 20, or 30 tig of Sch 21420 (prepared by one of the investigators) or 10 or 30 yg of amikacin (BBL Microbiology Systems, Cockeysville, Md.). Gentamicin and tobramycin disks (BBL) were also tested against the control strains. All controls performed satisfactorily; i.e., zones were within the NCCLS control limits (10) .
A previously described (1, 3, 13) microdilution procedure was used to determine the MICs of Sch 21420 (Schering Corp., Bloomfield, N.J.) and amikacin (Bristol Laboratories, Syracuse, N.J.). Both drugs are known to be affected by divalent cations in the test medium (7, 13, 14). For monitoring the performance of the broth medium that was used, gentamicin and tobramycin were also included in tests with the control strains. Performance of the cation-supplemented Mueller-Hinton broth used in these studies was measured by testing the control strain of Pseudomonas aeruginosa (ATCC 27853): MICs recorded on five separate occasions during the study were 4 or 8 jig of amikacin per ml, 8 olated from the regression lines. Examination of the scattergrams (Fig. 1) strains with MICs of 16 ,.g/ml in the intermediate category. The width to the intermediate category could also be reduced by adding 1 mm to the breakpoint for the resistant category without adding a significant number of major interpretive discrepancies. Such changes would increase the number of minor discrepancies (intermediate versus susceptible or resistant). Modifications of interpretive criteria should be held as possible options that can be considered after more clinical experience with Sch 21420 has been gathered which specifically documents the response of patients infected with organisms that require 16 ,ug/ml for inhibition.
With appropriate zone size interpretive standards, Sch 21420 tests with 10-, 20-and 30-ug disks were all reasonably accurate. However, the breakpoints for 10-,ug disks involve relatively small zones of inhibition; consequently, more potent disks are preferred (8, 15) . The regression formulas demonstrate that the 20-ug Sch 21420 disks give zones about the same size as those given by 30-,ug amikacin disksi thus, the same interpretive standards should apply to either disk. However, the assumption was not supported by the data in Fig. 1 . Because of the broad distribution of endpoints on either side of the regression line, interpretive zone standards were not based upon the regression analysis alone. When the error rate-bounded method was used to minimize interpretive discrepancies, zone standards for 30-,ug Sch 21420 disks were the same as those for 30-,ug amikacin disks.
Amikacin disk test data are summarized in Fig. 2 
